tranexamic acid

(redirected from Lysteda)
Also found in: Encyclopedia.

tranexamic acid

 [tran″ek-sam´ik]
an agent that combats fibrinolysis by competitively inhibiting activation of plasminogen; used in prophylaxis and treatment of hemorrhage associated with excessive fibrinolysis, such as that following oral surgery in patients with hemophilia; administered orally or intravenously.

tran·ex·am·ic ac·id

(tran'eks-am'ik as'id),
A competitive inhibitor of plasminogen activation and of plasmin; used in hemophilia to reduce or prevent hemorrhage.

tranexamic acid

/tran·ex·am·ic ac·id/ (tran″ek-sam´ik) an antifibrinolytic that competitively inhibits activation of plasminogen; used as a hemostatic in the prophylaxis and treatment of severe hemorrhage associated with excessive fibrinolysis.

tranexamic acid

[tran′ek-sam′ik]
an agent that combats fibrinolysis by competitively inhibiting activation of plasminogen. It is used in prophylaxis and treatment of hemorrhage associated with excessive fibrinolysis, such as that after oral surgery in patients with hemophilia. It is administered orally or intravenously.

tranexamic acid

A drug that interferes with the dissolution of blood clot (fibrinolysis) and can be used to prevent bleeding during minor operations such as tooth extraction in people with HAEMOPHILIA. A brand name is Cyklokapron.

tranexamic acid

an antifibrinolytic agent, used orally or intravenously to control hemorrhage. Called also Vasolamin.
References in periodicals archive ?
Lysteda is a nonhormonal lysine analog that acts as a competitive plasmin inhibitor; it is not a contraceptive.
The acquisition of LYSTEDA, in addition to our ongoing support of research and medical education in the field of Reproductive Health, demonstrates this significant commitment and represents an important addition to our Women's Health portfolio.
According to the FDA, Lysteda (Xanodyne Pharmaceuticals) is the first non-hormonal product approved for heavy menstrual bleeding, which affects about 3 million women a year.
Disclosures: The study was funded by Xanodyne Pharmaceuticals and Ferring Pharmaceuticals, which acquired global marketing rights to Lysteda last May.
According to the FDA, Lysteda, made by Xanodyne Pharmaceuticals, is the first nonhormonal product approved for heavy menstrual bleeding.
Lysteda is indicated for the treatment of cyclic heavy menstrual bleeding.
They include: BRAVELLE (urofollitropin for injection, purified), MENOPUR (menotropins for injection, USP) and REPRONEX (menotropins for injection, USP), NOVAREL (chorionic gonadotropin for injection, USP), ENDOMETRIN (progesterone) Vaginal Insert, LYSTEDA (tranexamic acid tablets), FIRMAGON (degarelix for injection), and EUFLEXXA (1% sodium hyaluronate).
1) According to a recent retrospective analysis of the 6-cycle pivotal trial that supported product approval, women taking LYSTEDA (tranexamic acid) Tablets, 3.
In clinical studies, LYSTEDA was shown to lower the amount of blood lost during monthly periods by about one third.
The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.